PFE - IPO Update: iTeos Therapeutics Finalizes IPO Plan
Quick Take
iTeos Therapeutics (ITOS) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing a range of treatments for various cancers, including solid tumors.
ITOS is pursuing treatments for highly prevalent cancer conditions, such as solid tumors and the IPO appears reasonably valued.
Company & Technology
Cambridge, Massachusetts-based iTeos was founded to develop treatments for a wide range of solid tumor, blood and other cancers that enhance the body's immune system to improve cancer targeting effects.